$0.77
Value $192M
LCTX and TMO stock compared: price, dividend, valuation and results, from SEC filings.
$0.77
Value $192M
$669.54
Value $249B
Lineage Cell Therapeutics (LCTX) has a market value of $192M and Thermo Fisher Scientific (TMO) $249B. Over the last year, with dividends, LCTX moved -55.0% and TMO +17.1%. Dividend yield: LCTX none, TMO 0.27%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LCTX$192M
TMO$249B
TMO is 1,294 times LCTX
Revenue, 12 months
LCTX$11M
TMO$47.4B
TMO is 4,370 times LCTX
Net income, 12 months
LCTX$1.8M
TMO$7.1B
TMO is 4,034 times LCTX
Operating margin
LCTX-280.3%
TMO17.9%
298.2 points apart
ROIC
LCTX-48.3%
TMO8.2%
56.5 points apart
P/E
LCTX–
TMO35.2
Dividend yield
LCTX0.0%
TMO0.3%
0.3 points apart
5-year return
LCTX-66.4%
TMO+6.8%
73.2 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LCTX-66.4%
TMO+6.8%
| Period | LCTXWith dividends | TMOWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -55.0%Price -55.0% | +17.1%Price +16.7% |
| 3 years since November 20, 2023 | -28.0%-10.4% a yearPrice -28.0% | +44.1%+13.0% a yearPrice +42.7% |
| 5 years since November 19, 2021 | -66.4%-19.6% a yearPrice -66.4% | +6.8%+1.3% a yearPrice +5.3% |
| 10 years since November 22, 2016 | -76.2%-13.4% a yearPrice -76.2% | +381.6%+17.0% a yearPrice +368.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LCTXLineage Cell TherapeuticsTMOThermo Fisher Scientific
| Price | $0.77 | $669.54 |
|---|---|---|
| Market value | $192M | $249B |
| Enterprise value (EV) | $147M | $284B |
| P/E | – | 35.2 |
| P/E, 5-year median | – | 32.7 |
| P/B | 2.9 | 4.5 |
| EV/EBIT | – | 33.5 |
| Free cash flow yield | – | 3.1% |
| Revenue, 12 months | $11M | $47.4B |
|---|---|---|
| Net income, 12 months | $1.8M | $7.1B |
| Free cash flow, 12 months | -$26M | $7.6B |
| Earnings per share, 12 months | -$0.09 | $18.96 |
| Revenue growth, year on year | 53.2% | 3.9% |
| Revenue growth a year, past | +51.5%over 5 years | +6.7%over 5 years |
| EPS growth a year, past | – | +2.1%over 5 years |
| Gross margin | – | – |
|---|---|---|
| Operating margin | -280.3% | 17.9% |
| Net margin | 16.2% | 14.9% |
| ROIC | -48.3% | 8.2% |
| ROE | 3.5% | 13.4% |
| Cash | $45M | $6.1B |
|---|---|---|
| Total debt | $2.0M | $41.4B |
| Net debt / EBITDA | – | 3.7 |
| Interest cover | – | 5.5× |
| Dividend yield | – | 0.3% |
|---|---|---|
| Dividend per share, 12 months | – | $1.84 |
| Dividend growth a year, past | – | +14.3%over 5 years |
| Buyback yield | – | 1.2% |
| Shareholder yield | – | 1.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Thermo Fisher Scientific ($249B) is about 1,293.6 times Lineage Cell Therapeutics ($192M), at today's prices.
Since November 22, 2016, LCTX's price moved -76.2% and TMO's +368.2%. With dividends: LCTX -76.2% (-13.4% a year), TMO +381.6% (+17.0% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Lineage Cell Therapeutics and 0.27% for Thermo Fisher Scientific. Over the last twelve months they paid – and $1.84 per share.
Over the last twelve months, the net margin was 16.2% for Lineage Cell Therapeutics and 14.9% for Thermo Fisher Scientific, and the operating margin -280.3% and 17.9%. Revenue was $11M and $47.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.